Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Pharmaceutical Research

Volumn 32, Issue 11, 2015, Pages 3470-3479

  Kamath, Amrita V ^a   Iyer, Suhasini ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody drug conjugate; biotherapeutics; cancer; pharmacokinetics; preclinical

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY CYTOTOXIC DRUG CONJUGATE; ANTIBODY DRUG CONJUGATE; CYTOTOXIC AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

DRUG CLEARANCE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG METABOLISM; DRUG RELEASE; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; ANIMAL; BIOTRANSFORMATION; DOSE RESPONSE; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOCONJUGATES; MOLECULAR TARGETED THERAPY;

EID: 84943585563     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1584-z     Document Type: Review

References (53)

1. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15-29.
2. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2012;76(2):248-62.
3. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341:1192-8.
4. Carter PJ, Senter PD. Antibody-drug conjugates for cancer Therapy. Cancer J. 2008; 154-169.
5. Prabhu S, Boswell CA, Leipold D, Khawli LA, Li D, Lu D, et al. Ther Deliv. 2011;2(6):769-91.
6. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529-37.
7. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12:329-32.
8. Beck A, Reichert JM. Antibody-drug conjugates: present and future. mAbs. 2014;15-17.
9. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29:2354-66.
10. Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6(1):34-45.
11. Kaur S, Xu K, Saad OM, Dere FC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 2013;5(2):201-26.
12. Alley SC, Anderson KE. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. Curr Opin Chem Biol. 2013;17:406-11.
13. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, et al. Bioanalysis of antibody-drug conjugates: American association of pharmaceutical scientists antibody-drug conjugate working group position paper. Bioanalysis. 2013;5(9):997-1006.
14. Xu K, Liu L, Saad OM, Baudys J, Williams L, Leipold D, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412:56-66.
15. Xu K, Liu L, Dere R, Mai E, Erickson R, Hendricks A, et al. Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum. Bioanalysis. 2013;5(9):1057-71.
16. Hengel SM, Sanderson R, Valliere-Douglass J, Nicholas N, Leiske C, Alley SC. Measurement of in vivo drug load distribution of cysteine-linked antibody-drug conjugates using microscale liquid chromatography mass spectrometry. Anal Chem. 2014;86(7):3420-5.
17. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30:184-9.
18. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426-33.
19. Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, et al. Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. 2013;273(2):298-313.
20. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698-704.
21. Adcetris. EMA CHMP Assessment report. 2012.
22. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21.
23. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548-58.
24. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamics considerations for drug development? Expert Opin Drug Metab Toxicol. 2012;8(2):141-60.
25. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11(1):20-33.
26. Pastuskovas CV, Mallet W, Clark S, Kenrick M, Majidy M, Schweiger M, et al. Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos. 2010;38:2309-19.
27. Lovdal T, Anderson E, Brech A, Berg T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci. 2000;113:3255-66.
28. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063-70.
29. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22(10):1994-2004.
30. Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, et al. Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers. Clin Cancer Res. 2009;15(21):6709-15.
31. Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2013;81:113-21.
32. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280-90.
33. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358-64.
34. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133-42.
35. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem. 2011;22(4):728-35.
36. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455-63.
37. A Safety Study of SGN-CD33A in AML Patients. ClinicalTrials.gov.
38. Okeley NM, Alley SC, Senter PD. Advancing antibody drug conjugation from the laboratory to a clinically approved anticancer drug. Hematol Oncol Clin N Am. 2014;28:13-25.
39. Leipold DD, Jumbe N, Duggar D, Crocker L, Leach W, Sliwkowski MX, et al. Trastuzumab-Mc-vc-PAB-MMAF: the effects of the drug: antibody ratio (DAR) on efficacy, toxicity and pharmacokinetics. AACR Annual Meeting 2007, Abstract #1551.
40. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925-32.
41. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16:4769-78.
42. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther. 2009;330(3):932-8.
43. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-65.
44. Strop P, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol. 2013;20(2):161-7.
45. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012;14(4):799-805.
46. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 2012;13(7):901-10.
47. Doronina SO, Setter JR, Hunter JH, Bovee TD, Anderson ME, Jonas M, et al. Elucidating the role of drug-linker hydrophobicity in the disposition of antibody-drug conjugates. AACR Annual Meeting 2014, Abstract #4470.
48. Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer. AAPS J. 2014; Epub ahead of print.
49. Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012;92(4):520-7.
50. Lu D, Girish S, Gao Y, Wang B, Yi JH, Guardino E, et al. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014; Epub ahead of print.
51. Gibiansky L, Gibiansky E. Target-mediated drug disposition model and its approximations for antibody-drug conjugates. J Pharmacokinet Pharmacodyn. 2014;41(1):35-47.
52. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643-59.
53. Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, et al. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn. 2013;40(5):557-71.